KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) EBT (2016 - 2026)

Pacific Biosciences Of California has reported EBT over the past 16 years, most recently at -$40.2 million for Q4 2025.

  • For Q4 2025, EBT fell 1594.94% year-over-year to -$40.2 million; the TTM value through Dec 2025 reached -$546.1 million, down 76.41%, while the annual FY2025 figure was -$546.1 million, 76.41% down from the prior year.
  • EBT for Q4 2025 was -$40.2 million at Pacific Biosciences Of California, down from -$37.6 million in the prior quarter.
  • Over five years, EBT peaked at $2.7 million in Q4 2024 and troughed at -$426.4 million in Q1 2025.
  • A 5-year average of -$85.9 million and a median of -$71.4 million in 2022 define the central range for EBT.
  • Biggest five-year swings in EBT: soared 103.25% in 2024 and later plummeted 1594.94% in 2025.
  • Year by year, EBT stood at -$68.2 million in 2021, then dropped by 23.81% to -$84.4 million in 2022, then rose by 1.95% to -$82.7 million in 2023, then soared by 103.25% to $2.7 million in 2024, then tumbled by 1594.94% to -$40.2 million in 2025.
  • Business Quant data shows EBT for PACB at -$40.2 million in Q4 2025, -$37.6 million in Q3 2025, and -$41.9 million in Q2 2025.